Cellares Secures New Investment to Advance Global Cell Therapy Manufacturing Infrastructure

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announced that Prime Radiant Fund SLP SICAV-RAIF, a fund advised by Prime Radiant Partners, has made a $50 million growth equity investment in the company’s Series D financing, bringing the total Series D to $327 million. 

“Cell therapy has moved from scientific promise to commercial reality, but the manufacturing infrastructure to support it at scale does not yet exist at the level the market will need,” said Walid Gardezi, Co-Founder and Partner at Prime Radiant Partners. “Cellares is building that infrastructure across the markets where these therapies will be delivered. Our roots in European pharma services give us a meaningful perspective on what it takes to operate in those markets, and we will be active partners in supporting Cellares’ expansion in Europe.”

“A global cell therapy manufacturing network has to be built in all major markets at once,” said Fabian Gerlinghaus, Co-Founder and CEO of Cellares. “Prime Radiant’s operational depth in pharma services across continental Europe makes them a strategic partner as we expand our manufacturing presence in Europe. The investors who have joined this Series D reflect the strength of the platform and the scale of what comes next.”

The investment supports the next phase of Cellares’ global Smart Factory buildout. Cellares’ European manufacturing facility, under construction in Leiden, the Netherlands, is designed to serve drug sponsors across global markets with the same automated manufacturing infrastructure available in the United States and will be GMP-ready in 2027. Prime Radiant’s experience in European healthcare services, anchored by offices in Milan and Munich, positions it to support Cellares’ expansion as demand for automated cell therapy manufacturing grows across the region.